Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T15:52:21.773Z.
Calculation as of: 2026-10-06T15:52:21.773Z.
Quote observation: 2026-10-06T15:46:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 127c42f84a692115bc317292f5e8c44ad9cea602a51c3ca4b81ff92f7edcc32f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$83.04M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$85.55M
EV/EBIT Ratio
N/A
TTM Avg
12.93x
3Y Avg
47.97x
5Y Avg
47.97x
Market Cap
$85.01M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nutriband Inc. (NTRB) | $80.47M | N/A | N/A | N/A | N/A |
| LENSAR Inc (LNSR)vs › | $82.29M | N/A | N/A | N/A | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $82.26M | N/A | N/A | N/A | N/A |
| MediciNova, Inc. (MNOV)vs › | $82.75M | N/A | N/A | N/A | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $83.04M | N/A | N/A | N/A | N/A |
| Pulmonx Corporation (LUNG)vs › | $79.98M | N/A | N/A | N/A | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.76M | N/A | N/A | N/A | N/A |
| ProMIS Neurosciences, Inc. (PMN)vs › | $85.55M | N/A | 12.93x | 47.97x | 47.97x |
| Cognition Therapeutics, Inc. (CGTX)vs › | $85.01M | N/A | N/A | N/A | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $85.17M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
